The novel SyqeÂ® The inhaler with its precision dosage helps relieve symptoms with lower risk of side effects
TORONTO, April 28, 2021 / CNW / – Syqe MedicalÂ®, a global leader in pharmaceutical and technological technology, today announces that Health Canada has approved the SyqeÂ® Inhaler, the first pharmaceutical grade medical cannabis delivery device system that provides predictable and consistent dosing per inhalation.
The SyqeÂ® The inhaler’s metered delivery system allows the patient to benefit from very low doses of medical cannabis and its unique, user-friendly design is easy to understand and use for physicians and patients alike.
“Syqe MedicalÂ® is proud to bring this first-class device, which delivers a specific dose of cannabinoids with each inhalation, helping to relieve symptoms with little or no adverse reactions, âsaid Perry davidson, founder and CEO of Syqe MedicalÂ®. âWe hope that the SyqeÂ® The inhaler will help alleviate doctors’ concerns about side effects and psychoactivity when prescribing medical cannabis. “
According to a recent post-marketing report, patients using the SyqeÂ® The inhaler, at one year and beyond, did not report any adverse effects.I
Due to its predictable, accurate and consistent microgram dosing capability, the new drug delivery technology helps remove the uncertainty around dosing and allows physicians to consider and recommend appropriate doses of cannabis. medical with more consistent results.
“This proprietary technology has great potential for the medical use of cannabis,” said Dr. Peter M. Blecher, Medical Director, CPM Centers for Pain Management. âCannabis for medical use has been hampered by unreliable dosing methods, such as smoking, and doctors have searched for a suitable alternative. Finding the dose that provides a consistent result has been problematic for healthcare professionals.Â® The inhaler, with its precision and consistent micro-dosing capability, can satisfy this unmet need. It is now possible to provide relief to patients without adverse effects. “
A multiple-dose, double-blind, placebo-controlled study conducted by Syqe MedicalÂ® and published in the European Journal of Pain confirmed that microgram doses of THC (the main psychoactive component of cannabis) administered via the SyqeÂ® The inhaler may be effective in relieving pain without psychoactive effects.ii
Study shows that an optimal effective dose is 500 micrograms of THC – A typical medical cannabis patient consumes one gram of 15 percent THC cannabis per day, which contains 150,000 micrograms of THC, 100 times the amount needed for relief pain. As a result, the study shows that when THC is delivered with greater precision to the patient, lower doses are needed, resulting in greater overall efficacy and fewer side effects, such as potentially debilitating psychoactivity. . Therefore, as the study demonstrates, the SyqeÂ® The inhaler with its first-class metered dosing capabilities and pre-filled medical cannabis cartridges allows first-time patients to benefit from predictable microgram doses of THC with unprecedented precision and low risk of side effects unwanted.
“Before being approved in Canada, the technology used in the SyqeÂ® The inhaler has undergone ten years of research and development, including testing in a variety of research trials, âsaid Michael milloy, Managing Director of Syqe MedicalÂ® in Canada. “We are proud of the extensive research that has been carried out to bring the inhaler to Canada and the rigorous clinical evidence that supports its use. “
The SyqeÂ® The inhaler will be available through Syqe MedicalÂ® Canada in partnership with a licensed Canadian producer for people with a valid medical authorization document.
About Syqe Â® Inhaler
The SyqeÂ® The inhaler is the first pharmaceutical grade medical cannabis delivery device system. It is a portable, single patient device designed to accurately aerosolize multiple doses of raw granulated herbs. During two seconds of heating and aerosolization, initiated by the actuation of respiration, THC acid undergoes a process of decarboxylation into the form of pharmacologically active THC. The device engages automatic temperature and flow rate controllers that ensure aerosol delivery of cannabinoids to the lungs, regardless of the individual patient’s inhalation pattern. Thereafter, the device requires minimal inhalation training.
About Syqe MedicalÂ®
Syqe MedicalÂ® is a pharmaceutical technology company developing technologies that allow precise delivery of a wide range of therapeutic molecules by inhalation. Using its new technology, Syqe MedicalÂ® aims to relieve the suffering of as many patients as possible in the fastest possible way. The revolutionary Syqe drug delivery technology now enables hundreds of existing and preclinical drug molecules to be considered for inhalation, radically altering their clinical profile and addressing significant unmet needs. For more information, visit: www.syqemedical.com.
I Data on file
ii Almog, S., Aharon-Peretz, J., Vulfsons, S., et al. The pharmacokinetics, efficacy, and safety of a novel dose-selective cannabis inhaler in patients with chronic pain: a randomized, double-blind, placebo-controlled trial. European Pain Journal. May 23, 2020. https://doi.org/10.1002/ejp.1605
SOURCE Syqe Medical
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2021/28/c4866.html